ARWR - Arrowhead Pharmaceuticals, Inc. EV/EBITDA Multiple

The fate of Arrowhead Pharmaceuticals (ARWR) depends on clinical trial outcomes, making R&D control critical. The business valuation via EV/EBITDA clearly demonstrates these fluctuations, and the current level of this metric is 0.00. The company's foundation is the unique TRiM platform for targeted gene silencing, and its strategy is based on creating breakthrough drugs for lung and liver therapies.

ARWR (Arrowhead Pharma) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization history from 11/23/2025 to 11/12/2026

Comprehensive metric breakdowns and analytics for arrowheadpharma.com (ARWR)

- market price and analyst price targets:

Price Chart Arrowhead Pharmaceuticals Inc|ARWR - Price Target Chart

- market capitalization statistics:

Market Capitalization Arrowhead Corp|ARWR - Company Buyout Price

- issuer book value statistics:

Accounting Value per Share Arrowhead Pharmaceuticals|ARWR - Company Book Value|Market Capitalization to Book Value Ratio arrowheadpharma.com|ARWR - Company Assets

- company liabilities and liquidity data:

Debt to Equity Arrowhead Pharmaceuticals|ARWR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Arrowhead Pharmaceuticals, Inc.|ARWR - Company Aggregate Debts|Debt to Book Capitalization Ratio Arrowhead Corp|ARWR - Company Long-Term Loans and Borrowings|Company Short-Term Debt Arrowhead Pharmaceuticals|Quick Liquidity arrowheadpharma.com

- net income and valuation multiples indicators:

ARWR - Company Net Income|Future Profit Arrowhead Pharmaceuticals|ARWR - Price to Earnings Ratio|Forward P/E Multiple Arrowhead Pharmaceuticals|ARWR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Arrowhead Corp|ARWR - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Arrowhead Pharmaceuticals|ARWR - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth arrowheadpharma.com|ARWR - Earnings per share growth this year|Expected earnings per share growth for next year Arrowhead Pharmaceuticals

Fundamental company analysis:ARWR (Arrowhead Pharmaceuticals Inc)

The EV/EBITDA multiple determines the total enterprise value relative to operating profit, allowing for an assessment of a company's ability to service debt with real cash flow. By analyzing the EV/EBITDA trend for Arrowhead Pharmaceuticals (ARWR), an investor can see how the asset's stability depends on partner licensing payments, as the lack of internal pricing power makes this indicator a key marker of the biotech's solvency.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Mirum Pharma MIRM|Dynavax - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Arbutus Biopharma - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio inventivapharma.com IVA|GYRE (Gyre Therapeutics) - Enterprise Value to EBITDA Ratio|ASMB (Assembly Bio) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GALT (Galectin Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Genfit Corp GNFT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DURECT Corporation (DRRX)|ALGS (aligos.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BIVI (BioVie)|EV/EBITDA Multiple Galmed Pharmaceuticals Ltd GLMD|NDRA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation HEPA (Hepion Pharmaceuticals)